Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.

Conclusion Administrating pegfilgrastim on day 3 or later may prevent FN more effectively among Japanese breast cancer patients receiving intermediate-risk chemotherapies.
PMID: 29855985 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Hayama T, Sakurai K, Miura K, Washinosu S, Tsuboi S, Uchiike A, Yoshida Y, Takei M Tags: Int J Clin Pharm Source Type: research